Product Information
LISDEXAMFETAMINE 30 MG TB CHEW is a generic product labeled by Camber Pharmaceuticals Inc., priced at $3.2915 per EA under NDC 31722032301. Its NADAC has been published 91 times since Jan 8, 2025.
FDA first approved this application on Aug 25, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
30 mg/1
Manufacturer
Camber Pharmaceuticals Inc.NDC
31722032301
Classification
Generic
Dosage Form
TABLET, CHEWABLE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LISDEXAMFETAMINE DIMESYLATEApproval Type
Generic (ANDA)
FDA Application
ANDA217068FDA Approved
8/25/2023
TE Code
AB
On Market Since
8/25/2023
Pharmacological Classes
Price Statistics
The NADAC for LISDEXAMFETAMINE 30 MG TB CHEW has been published 91 times since Jan 8, 2025, and over the history we have for it it has declined 56.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3.2915 per EA |
|---|---|
| All-time high | $7.7532 (Apr 16, 2025) |
| All-time low | $3.2915 (Sep 23, 2026) |
| 52-week high | $7.3210 |
| 52-week low | $3.2915 |
| Median price | $6.5950 |
| Average price | $6.0911 |
| Largest weekly change | -17.2% (Jul 22, 2026) |
| Weeks tracked | 91 |
| Tracking since | Jan 8, 2025 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Camber Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
lisdexamfetamine dimesylate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central Nervous System Stimulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LISDEXAMFETAMINE 30 MG TB CHEW?
The current National Average Drug Acquisition Cost (NADAC) for LISDEXAMFETAMINE 30 MG TB CHEW, manufactured by Camber Pharmaceuticals Inc., is $3.2915 per EA (NDC 31722032301), effective Sep 30, 2026.
How has the price of LISDEXAMFETAMINE 30 MG TB CHEW changed over time?
Over the history we have for it, the NADAC for LISDEXAMFETAMINE 30 MG TB CHEW has declined 56.5%. It has been tracked across 91 weekly CMS publications since Jan 8, 2025.
What are the highest and lowest recorded NADAC prices for LISDEXAMFETAMINE 30 MG TB CHEW?
Since Jan 8, 2025, the NADAC for LISDEXAMFETAMINE 30 MG TB CHEW has ranged from a low of $3.2915 (Sep 23, 2026) to a high of $7.7532 (Apr 16, 2025), with a median of $6.5950 per EA.
Are there cheaper alternatives to LISDEXAMFETAMINE 30 MG TB CHEW?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as LISDEXAMFETAMINE 30 MG TB CHEW in a comparable dosage form, but none are currently priced below it.
Who manufactures LISDEXAMFETAMINE 30 MG TB CHEW?
LISDEXAMFETAMINE 30 MG TB CHEW (NDC 31722032301) is labeled by Camber Pharmaceuticals Inc., and CMS classifies it as a generic product.